These findings pave the way for the development of a new class of improved cancer therapeutics which could have a complementary mechanism of action and potentially enhanced safety profile in comparison to existing angiogenesis inhibitors.
Angiogenesis inhibitors are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutriments. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. Currently available angiogenesis inhibitors specifically target vascular endothelial growth factor (VEGF), which plays an important role in promoting the formation of blood vessels. However, since VEGF inhibitors also act on healthy tissue, their therapeutic potential is hampered by side effects. Although PlGF is a homologue of VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue.
Based on its anti-angiogenic properties, ThromboGenics and BioInvent also intend to develop TB-403 for eye diseases, to block uncontrolled blood vessel growth in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy.
Prof. Desire Collen, CEO and Chairman of ThromboGenics, commented:
"Today's publication in the prestigious journal Cell clearly highlights our
ground-breaking research in the field of angiogenesis. The data in the Cell
paper shows the potential of our novel anti-PlGF antibody, TB-403, based on
its unique ability to block the development of new blood vessels, but only
via mechanisms that exist in the diseased state. This mode of action, which
is different from and complementary to current anti-VEGF inhibitors, makes
it attractive as both a stand-alone and combination therapy. I am very
excited that we w
|SOURCE ThromboGenics NV|
Copyright©2007 PR Newswire.
All rights reserved